Effect of a multispecies Probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial

Journal of Research in Medical Sciences

Volumn 19, Issue 9, 2014, Pages 827-833

  Sanaie, Sarvin ^a   Ebrahimi Mameghani, Mehrangiz ^a   Hamishehkar, Hadi ^b   Mojtahedzadeh, Mojtaba ^b   Mahmoodpoor, Ata ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Inflammation; Probiotics; Sepsis

Indexed keywords

BIOLOGICAL MARKER; INFLAMMATORY MARKER; INTERLEUKIN 6; PLACEBO; PROBIOTIC AGENT; PROCALCITONIN; PROTEIN C; UNCLASSIFIED DRUG;

ADULT; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BIFIDOBACTERIUM; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LACTOBACILLUS; MALE; NASOGASTRIC TUBE; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; STREPTOCOCCUS THERMOPHILUS;

EID: 84913591085     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
2. Centers for Disease Control (CDC). Increase in National Hospital Discharge Survey rates for septicemia-United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990;39:31-4.
3. Eslami K, Mahmoodpoor A, Ahmadi A, Abdollahi M, Kamali K, Mousavi S, et al. Positive effect of septimeb™ on mortality rate in severe sepsis: A novel non antibiotic strategy. Daru 2012;20:40.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
5. Takala A, Nupponen I, Kylänpää-Bäck ML, Repo H. Markers of inflammation in sepsis. Ann Med 2002;34:614-23.
6. Haasper C, Kalmbach M, Dikos GD, Meller R, Müller C, Krettek C, et al. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. Technol Health Care 2010;18:89-100.
7. Hamishehkar H, Beigmohammadi MT, Abdollahi M, Ahmadi A, Mahmoodpour A, Mirjalili MR, et al. Identification of enhanced cytokine generation following sepsis. Dream of magic bullet for mortality prediction and therapeutic evaluation. Daru 2010;18:155-62.
8. Farhoudi M, Najafi-Nesheli M, Hashemilar M, Mahmoodpoor A, Sharifipour E, Baradaran B, et al. Effect of IMOD™ on the inflammatory process after acute ischemic stroke: A randomized clinical trial. Daru 2013;21:26.
9. Balci C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003;7:85-90.
10. Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993;70:29-35.
11. Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28:S49-56.
12. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: The role of the gut. Shock 2001;15:1-10.
13. MacFie J, O’Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth P. Gut origin of sepsis: A prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999;45:223-8.
14. MacFie J. Current status of bacterial translocation as a cause of surgical sepsis. Br Med Bull 2004;71:1-11.
15. Murono K, Hirano Y, Koyano S, Ito K, Fujieda K. Molecular comparison of bacterial isolates from blood with strains colonizing pharynx and intestine in immunocompromised patients with sepsis. J Med Microbiol 2003;52:527-30.
16. Alberda C, Gramlich L, Meddings J, Field C, McCargar L, Kutsogiannis D, et al. Effects of probiotic therapy in critically ill patients: A randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2007;85:816-23.
17. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244-50.
18. Yan F, Polk DB. Probiotics as functional food in the treatment of diarrhea. Curr Opin Clin Nutr Metab Care 2006;9:717-21.
19. Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002;97:2150-2.
20. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: A review of clinical trials. Proc Nutr Soc 2007;66:307-15.
21. Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010;51:24-30.
22. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
23. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
24. Morrow LE. Probiotics in the intensive care unit. Curr Opin Crit Care 2009;15:144-8.
25. Ebrahimi-Mameghani M, Sanaie S, Mahmoodpoor A, Hamishehkar H. Effect of a probiotic preparation (VSL#3) in critically ill patients: A randomized, double-blind, placebo-controlled trial (Pilot Study). Pak J Med Sci 2013;29:490-4.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29.
27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
28. McNaught CE, Woodcock NP, Anderson AD, MacFie J. A prospective randomised trial of probiotics in critically ill patients. Clin Nutr 2005;24:211-9.
29. Tabeefar H, Beigmohammadi MT, Javadi MR, Abdollahi M, Mahmoodpoor A, Ahmadi A, et al. Effects of Pantoprazole on Systemic and Gastric Pro-and Anti-inflammatory Cytokines in Critically Ill Patients. Iran J Pharm Res 2012;11:1051-8.
30. Blackwell TS, Christman JW. Sepsis and cytokines: Current status. Br J Anaesth 1996;77:110-7.
31. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: Early results of a randomized controlled trial. World J Surg 2006;30:1848-55.
32. Kunavue N, Lien TF. Effects of fulvic acid and probiotic on growth performance, nutrient digestibility, blood parameters and immunity of pigs. J Anim Sci Adv 2012;2:711-21.
33. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001;152:735-41.
34. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
35. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci U S A 2010;107:454-9.
36. Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Carbo A, Shaykhutdinov R, et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR? To suppress colitis. PLoS One 2012;7:e31238.
37. Najafi A, Mojtahedzadeh M, Mahmoodpoor A, Aghamohammadi M, Ahmadi A, Nahreini Sh, et al. Effect of N-acetylcysteine on microalbuminuria in patients with acute respiratory distress syndrome. Arch Med Sci 2009;3:408-14.
38. Mahmoodpoor A, Eslami K, Mojtahedzadeh M, Najafi A, Ahmadi A, Dehnadi-Moghadam A, et al. Examination of Setarud (IMOD™) in the management of patients with severe sepsis. Daru 2010;18:23-8.
39. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001;286:1754-8.
40. Tan M, Zhu JC, Du J, Zhang LM, Yin HH. Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: A prospective randomized pilot study. Crit Care 2011;15:R290.